Compare Summit Therapeutics Inc (SMMT) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs ProShares UltraPro S&P500 — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while ProShares UltraPro S&P500 trades at $147.41. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | UPRO | |
|---|---|---|
Market Cap | $13.98B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.38 | $157.66 |
52-Week Low | $12.43 | $89.29 |
Enterprise Value | $13.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
UPRO trades at $149.32, down 1.69% with neutral technical signals. The stock shows mixed technical indicators with bullish moving averages but neutral oscillators. Recent S&P 500 market discussions highlight AI-driven growth potential alongside concerns about high valuations and geopolitical risks. The stock faces support at $146 and resistance at $151, with overall market sentiment balanced between optimism and caution.
The outlook for UPRO remains tied to broader S&P 500 performance, with potential upside from AI productivity gains but risks from elevated valuations and interest rate uncertainty. Investors face a balanced risk-reward profile with technical support providing near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
